Last reviewed · How we verify
Estradiol+Drospirenone
Estradiol+Drospirenone is a Combined oral contraceptive Small molecule drug developed by Brigham and Women's Hospital. It is currently FDA-approved for Contraception, Treatment of premenstrual dysphoric disorder (PMDD). Also known as: Angeliq.
Estradiol and drospirenone work together as a hormonal contraceptive by suppressing ovulation through negative feedback on the hypothalamic-pituitary-ovarian axis.
Estradiol and Drospirenone are components of an oral contraceptive pill, which is used for contraception and the prevention of pregnancy. The combination of Estradiol and Drospirenone is also studied for its effects on various conditions, including cardiovascular diseases and adverse effects of oral contraceptives.
At a glance
| Generic name | Estradiol+Drospirenone |
|---|---|
| Also known as | Angeliq |
| Sponsor | Brigham and Women's Hospital |
| Drug class | Combined oral contraceptive |
| Target | Estrogen receptors (ER-α, ER-β) and progesterone receptors (PR); mineralocorticoid receptor antagonism |
| Modality | Small molecule |
| Therapeutic area | Contraception / Gynecology |
| Phase | FDA-approved |
Mechanism of action
Estradiol (a natural estrogen) and drospirenone (a progestin with antimineralocorticoid activity) inhibit the release of gonadotropin-releasing hormone (GnRH), which prevents the surge of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) needed for ovulation. Drospirenone additionally provides progestational effects and mild antimineralocorticoid activity, enhancing contraceptive efficacy and providing additional benefits such as reduced bloating.
Approved indications
- Contraception
- Treatment of premenstrual dysphoric disorder (PMDD)
Common side effects
- Nausea
- Headache
- Breast tenderness
- Breakthrough bleeding
- Mood changes
- Venous thromboembolism
Key clinical trials
- A Drug-drug Interaction Study of Vorasidenib and a Combined Oral Contraceptive in Healthy Female Participants (PHASE1)
- Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants (PHASE1)
- Oral Contraceptive Pills Versus Levonorgestrel-Releasing Intrauterine System for Niche-Related Abnormal Uterine Bleeding (NA)
- A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies (PHASE1)
- Effect of Drospirenone-Ethinyl Estradiol (20microgram vs 30 Microgram) on Free Androgen Index in PCOS (NA)
- Efficacy of Oral Contraceptive, Progesterone, and Inositol on Menstrual Regulation in PCOS (NA)
- Continuous Versus Cyclical OCP Use in PCOS (PHASE4)
- Ultra-Safe Hormonal Strategy: Transdermal Estradiol Added to Progestins for Endometriosis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Estradiol+Drospirenone CI brief — competitive landscape report
- Estradiol+Drospirenone updates RSS · CI watch RSS
- Brigham and Women's Hospital portfolio CI
Frequently asked questions about Estradiol+Drospirenone
What is Estradiol+Drospirenone?
How does Estradiol+Drospirenone work?
What is Estradiol+Drospirenone used for?
Who makes Estradiol+Drospirenone?
Is Estradiol+Drospirenone also known as anything else?
What drug class is Estradiol+Drospirenone in?
What development phase is Estradiol+Drospirenone in?
What are the side effects of Estradiol+Drospirenone?
What does Estradiol+Drospirenone target?
Related
- Drug class: All Combined oral contraceptive drugs
- Target: All drugs targeting Estrogen receptors (ER-α, ER-β) and progesterone receptors (PR); mineralocorticoid receptor antagonism
- Manufacturer: Brigham and Women's Hospital — full pipeline
- Therapeutic area: All drugs in Contraception / Gynecology
- Indication: Drugs for Contraception
- Indication: Drugs for Treatment of premenstrual dysphoric disorder (PMDD)
- Also known as: Angeliq
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing